Hobbs Group Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Hobbs Group Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$505K	Buy	810 +542	+202%	+$369K	0.13%	107
2026 Q1	$207K	Sell	268 -47	-15%	-$36K	0.06%	154
2025 Q4	$243K	Buy	+315	New	+$214K	0.07%	152
2025 Q3	–	Sell	-387	Closed	-$203K	–	163
2025 Q2	$203K	Sell	387 -545	-58%	-$304K	0.07%	142
2025 Q1	$591K	Buy	+932	New	+$641K	0.22%	85
2024 Q4	–	Sell	-258	Closed	-$271K	–	502
2024 Q3	$271K	Hold	258	–	–	0.1%	120
2024 Q2	$271K	Buy	+258	New	+$250K	0.1%	122
2023 Q4	$263K	Buy	+300	New	+$247K	0.12%	109

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hobbs Group Advisors's REGN Position: Q2 2026 in Review

Hobbs Group Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 202% in Q2 2026, buying an estimated $369K and bringing the position to 810 shares worth $505K. The position accounts for 0.13% of the portfolio, ranked #107.

Hobbs Group Advisors first reported a position in REGN in Q4 2023 and has held it in 8 quarters since. The position peaked at $591K in Q1 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Hobbs Group Advisors held 810 shares of Regeneron Pharmaceuticals worth $505K as of Q2 2026.
Hobbs Group Advisors bought 542 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $369K.
Regeneron Pharmaceuticals made up 0.13% of Hobbs Group Advisors's portfolio in Q2 2026, its #107 holding.
Hobbs Group Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Hobbs Group Advisors's Regeneron Pharmaceuticals position peaked at $591K in Q1 2025.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hobbs Group Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.